The Kasumi-1 cell line: A t(8;21)-kit mutant model for acute myeloid leukemia

Leukemia and Lymphoma

Volumn 46, Issue 2, 2005, Pages 247-255

  Larizza, Lidia ^a   Magnani, Ivana ^a   Beghini, Alessandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

c kit activating mutation; c kit amplification; Core Binding Factor Leukemia; Kasumi 1 cell line; KIT mutant mediated signal transduction; STI 571; t(8; 21)

Indexed keywords

ASPARAGINE; CORE BINDING FACTOR; HYBRID PROTEIN; IMATINIB; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STEM CELL FACTOR; TRICHOSTATIN A; TYROSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CANCER MODEL; CANCER STAGING; CELLULAR DISTRIBUTION; CHROMOSOME TRANSLOCATION 8; GENE ACTIVATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ACUTE DISEASE; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; HUMANS; LEUKEMIA, MYELOID; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 13244279499     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400007565     Document Type: Article

References (67)

1. Asou, H., Tashiro, S., Hamamoto, K., Otsuji, A., Kita, K. and Kamada, N. (1991) "Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation", Blood, 77 9), 2031-2036.
2. Speck, N.A. and Gilliland, D.G. (2002) "Core-binding factors in haematopoiesis and leukaemia", Nature Reviews Cancer, 2, 502-513.
3. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., et al. (1999) "KIT proto-oncogene exon 8 inframe deletion plus insertion mutations in acute myeloid leukaemia", British Journal of Haematology, 105, 894-900.
4. Beghini, A., Peterlongo, P., Ripamonti, C.B., Larizza, L., Cairoli, R., Morra, E., et al. (2000a) "C-kit mutations in core binding factor leukemias", Blood, 95(2), 726-727.
5. Beghini, A., Magnani, I., Ripamonti, C.B. and Larizza, L. (2002) "Amplification of a novel c-Kit activating mutation Asn(822 -Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia", The Hematology Journal, 3(3), 157-163.
6. Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C.J., et al. (2001) "AML1-ETO expression is directly involved in the development of AML in the presence of additional mutations", Proceedings National Academy of Sciences (USA), 98 18), 10398-10403.
7. Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J. and Downing, J.R. (2002) "Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukaemia", Cancer Cell, 1, 63-74.
8. Kelly, L.M. and Gilliland, D.G. (2002) "Genetics of myeloid leukemias", Annual Reviews of Genomics and Human Genetics, 3 179-198.
9. Beghini, A., Ripamonti, C.B., Castorina, P., Pezzetti, L., Doneda, L., Cairoli, R., et al. (2000b) "Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement", Cancer Genetics and Cytogenetics, 119, 26-31.
10. Heinrich, M.C., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A. and Zigler, A.J. (2000). "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96(3), 925-932.
11. Ma, Y., Zeng, S., Metcalfe, D.D., Akin, C., Dimitrijevic, S., Butterfield, J.H., et al. (2002) "The c-Kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations", Blood, 99, 1741-1744.
12. Peterson, L.F. and Zhang, D.E. (2004) "The 8;21 translocation in leukemogenesis", Oncogene, 23, 4255-4262.
13. + immature cells", British Journal of Hematology, 97, 656-658.
14. Schwartz, S., Heinecke, A., Zimmermann, M., Creutzig, U., Schoch, C., Harbott, J., et al. (1999) "Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance", Leukemia and Lymphoma, 34 1-2), 85-94.
15. Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., et al. (1993) "The t(8;21) translocation in acute myeloid leukemia results in production of an AML-1-MTG8 fusion transcript", EMBO Journal, 12, 2715-2721.
16. Yergeau, D.A., Hetherington, C.J., Wang, Q., Zhang, P., Sharpe, A.H., Binder, M., et al. (1997) "Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene", Nature Genetics, 15, 303-306.
17. Okuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C.J., van Deursen, H., et al. (1998) "Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors", Blood, 91, 3134-3143.
18. Zhang, D.E., Fujioka, K., Hetherington, C.J., Shapiro, L.H., Chen, H.-M., Look, A.T., et al. (1994) "Identification of a region which directs the monocytic activity of the colony stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1)", Molecular & Cellular Biology, 14, 8085-8095.
19. Frank, R., Zhang, J., Uchida, H., Meyers, S., Hiebert, S.W. and Nimer, S.D. (1995) "The AML1-ETO protein blocks transactivation of GM-CSF promoter by AML1B", Oncogene, 11, 2667-2674.
20. Meyers, S., Lenny, N. and Hiebert, S.W. (1995) "The t(8;21) fusion protein interferes with AML1B-dependent transcriptional activity", Molecular and Cellular Biology, 15, 1974-1982.
21. Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P.G. and Lazar, M.A. (1998) "Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukaemia partner ETO". Molecular and Cellular Biology, 18, 7185-7191.
22. Wang, J., Oshino, T., Redner, R.L., Kajigaya, S. and Liu, J.M. (1998) "ETO, fusion partner in t(8;21) acute myeloid leukaemia, represses transcription by interaction with the human N-CoR/mSinHDAC1 complex", Proceedings National Academy of Sciences (USA), 95 10860-10865.
23. Wang, J., Saunthararajah, Y., Redner, R.L. and Liu, J.M. (1999) "Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukaemia cells", Cancer Research, 59, 2766-2769.
24. Melnick, A., Carlile, G.W., McConnell, M.J., Polinger, A., Hiebert, S.W. and Licht, J.D. (2000) "AML1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein", Blood, 96, 3939-3947.
25. Pabst, T., Mueller, B.U., Harakawa, T., Schoch, C., Haferlach, G., Behre, G., et al. (2001) "AML-1-ETO downregulates the granulocytic differentiation factor C/EBP alpha in t(8; 21) myeloid leukemia", Nature Medicine, 7, 444-451.
26. Jakubowiak, A., Pouponnot, C., Berguido, F., Frank, R., Mao, S., Massague, J., et al. (2000) "Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukaemia-associated fusion protein", Journal of Biological Chemistry 275, 40282-40287.
27. Vangala, R.K., Heiss-Neumann, M.S., Rangatia, J.S., Singh, S.M., Schoch, C., Tenen, D.G., et al. (2003) "The myeloid master regulator transcription factor PU.1 is inactivated by AML-ETO in t(8;21) myeloid leukaemia", Blood, 101, 270-277.
28. Matsushita, H., Kizaki, M., Kobayashi, H., Muto, A. and Ikeda, Y. (1999) "Induction of apoptosis in myeloid leukemic cells by ribozymes targeted against AML1/MTG8", British Journal of Cancer, 79, 1325-1331.
29. Heidenreich, O., Krauter, J., Riehle, H., Hadwiger, P., John, M., Heil, G., et al. (2003) "AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8:21)-positive leukemic cells", Blood, 101, 3157-3163.
30. Song, W.-J., Sullivan, M.G., Legare, R.D., Hitchings, S., Tan, X., Kufrin, D., et al. (1999) "Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia", Nature Genetics, 23, 166-175.
31. De Guzman, C.G., Warren, A.J., Zhang, Z., Gartland, L., Erickson, P., Drabkin, H., et al. (2002) "Hematopoietic stem cells expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation", Molecular and Cellular Biology 22(15), 5506-5517.
32. Wiemels, J.L., Xiao, Z., Buffler, P.A., Maia, A.T., Dicks, B.M., Smith, M.T., et al. (2002) "In utero origin of t(8;21) AML1-ETO translocation in childhood acute myeloid leukaemia", Blood, 99, 3801-3805.
33. Gilliland, D.G. (2001) "Hematologic malignancies", Current Opinions in Hematology, 8, 189-191.
34. Grisolano, J.L., O'Neal, J., Cain, J. and Tomasson, M.H. (2003) "An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice", Proceedings National Academy of Sciences (USA), 100(16), 9506-9511.
35. Gilliland, D.G. and Tallman, S.T. (2002) "Focus on acute leukemias", Cancer Cell, 1, 417-420.
36. Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., et al. (1997) "Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia study group of the Ministry of Health and Welfare (Kosheisho ", Leukemia, 11, 1447-1452.
37. Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., et al. (2003) " Incidence and prognosis of KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukemia", British Journal of Haematology, 121 775-777.
38. Beghini, A., Ripamonti, C.B., Cairoli, R., Cazzaniga, G., Colapietro, P., Elice, F., et al. (2004) "KIT activating mutations: incidence in adult and pediatric AML, and identification of an internal tandem duplication", Haematologica, 89, 920-925.
39. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., et al. (2001) "The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials". Blood, 98, 1752-1759.
40. Cairoli, R., Grillo, G., Beghini, A., Tedeschi, A., Ripamonti, C.B., Larizza, L., et al. (2003) "KIT point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index", Leukemia, 17, 471-472.
41. Nguyen, S., Leblanc, T., Fenaux, P., Witz, F., Blaise, D., Pigneux, A., et al. (2002) "A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup", Blood, 99, 3517-3523.
42. Zwaan, C.M., Meshinchi, S., Radich, J.P., Veerman, A.J., Huismans, D.R., Munske, L., et al. (2003) "FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance", Blood, 102(7), 2387-2394.
43. Serve, H., Yee, N.S., Stella, G., Sepp-Lorenzino, L., Tan, J.C. and Besmer, P. (1995) "Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells", EMBO Journal, 14(3), 473-483.
44. Zwaan, C.M., Miller, M., Goemans, B.F., Hahlen, K., vanWering, E., Meshinchi, S., et al. (2002) "Frequency and clinical significance of c-kit exon 17 mutations in childhood acute myeloid leukemia. [abstract]", Blood, 100(11), 2952.
45. d'Auriol, L., Mattei, M.G., Andre, C. and Galibert, F. (1988) "Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4", Human Genetics, 78(4), 374-376.
46. Beghini, A., Cairoli, R., Morra, E. and Larizza, L. (1998) "In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation", Blood Cells, Molecules & Diseases, 24(2), 262-270.
47. Nishii, K., Usui, E., Katayama, N., Lorenzo, F., Nakase, K., Kobayashi, T., et al. (2003) "Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML", Leukemia, 17(4), 731-737.
48. Langabeer, S.E., Beghini, A. and Larizza, L. (2003) "AML with t(8;21) and trisomy 4: possible involvement of KIT?", Leukemia 17, 1915.
49. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., et al. (2001) "Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukaemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukaemia group B study", Cancer Research, 61, 7233-7239.
50. Zhuang, Z., Park, W.-S., Pack, S., Schmidt, L., Vortmeyer, A.O., Pak, E., et al. (1998) "Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas", Nature Genetics, 20, 66-69.
51. Huang, S.C., Koch, C.A., Vortmeyer, A.O., Pack, S.D., Lichtenauer, U.D., Mannan, P., et al. (2000) "Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas", Cancer Research, 60(22), 6223-6226.
52. Tsujimura, T., Kanakura, Y. and Kitamura, Y. (1997) "Mechanisms of constitutive activation of c-kit receptor tyrosine kinase", Leukemia, 11(Suppl 3). 396-398.
53. Timokhina, I., Kissel, H., Stella, G. and Besmer, P. (1998) "Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation", EMBO Journal, 17(21), 6250-6262.
54. Chian, R., Young, S., Danilkovitch-Miagkova, A., Ronnstrand, L., Leonard, E., Ferrao, P., et al. (2001) " Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant", Blood, 98(5), 1365-1373.
55. Ning, Z.-Q., Li, J. and Arceci, R.J. (2001b) "Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells", Blood, 97(11), 3559-3567.
56. Hashimoto, K., Matsumura, I., Tsujimura, T., Kim, D.K., Ogihara, H., Ikeda, H., et al. (2003) "Necessity of tyrosine 719 and phosphatidylinositol 3′-kinase mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation", Blood, 101(3), 1094-1102.
57. Linnekin, D. (1999) "Early signaling pathways activated by c-kit in hematopoietic cells", International Journal of Biochemistry & Cell Biology, 31, 1053-1074.
58. Frost, M.J., Ferrao, P.T., Hughes, T.P. and Ashman, L.K. (2002) "Juxtamembrane mutant V560G Kit is more sensitive to Imatinib (STI571) compared with wild-type KIT whereas the kinase domain mutant D816V Kit is resistant", Molecular Cancer Therapeutics, 1, 1115-1124.
59. Okuda, K., Sanghera, J.S., Pelech, S.L., Kanakura, Y., Hallek, M., Griffin, J.D., et al. (1992) " Granulocyte-macrophage colony stimulating factor, interleukin-3 and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase", Blood, 79 2880-2887.
60. Spiekermann, K., Faber, F., Voswinckel, R. and Hiddemann, W. (2002) "The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells", Experimental Hematology, 30, 767-773.
61. Vivanco, I. and Sawyers, C.L. (2002) "The phosphatidylinositol 3-Kinase AKT pathway in human cancer", Nature Reviews Cancer, 2(7), 489-501.
62. Shivakrupa, R., Bernstein, A., Watring, N. and Linnekin, D. (2003) "Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant", Cancer Research 63(15), 4412-4419.
63. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., et al. (2000) "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration", Journal of Clinical Investigation, 106(4), 511-521.
64. List, A.F., Glinsmann-Gibson, B., Stadheim, C., Meuillet, E.J., Bellamy, W. and Powis, G. (2004) "Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells", Experimental Hematology, 32(6), 526-535.
65. Smolich, B.D., Yuen, H.A., West, K.A., Giles, F.J., Albitar, M. and Cherrington, J.M. (2001) "The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts", Blood, 97(5), 1413-1421.
66. Kindler, T., Breitenbuecher, F., Marx, A., Hess, G., Gschaidmeier, H., Gamm, H., et al. (2003) "Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML", Blood, 101(8), 2960-2962.
67. Ning, Z.-Q., Li, J. and Arceci, R.J. (2001a) "Activating mutations of KIT at codon 816 confer drug resistance in human leukemia cells", Leukemia and Lymphoma, 41(5-6), 513-522.